Interim recommendations for use of the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (‎CNBG)‎, Sinopharm

This interim guidance has been developed on the basis of the advice issued by the Strategic Advisory Group of Experts (SAGE) on Immunization at its extraordinary meeting on 29 April 2021. Declarations of interests were collected from all external contributors and assessed for any conflicts of interest. Summaries of the reported interests can be found on the SAGE meeting website and SAGE Working Group website. The guidance is based on the evidence summarized in the background document on the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (CNBG), Sinopharm and the annexes which include the GRADE and Evidence to Recommendation Tables. These documents are available on the SAGE COVID-19 webpage: https://www.who.int/groups/strategic-advisory-group of-experts-on-immunization/covid-19-materials. These interim recommendations refer to the inactivated COVID-19 vaccine (Vero cell), manufactured by the Beijing Institute of Biological Products Co., Limited (BIBP), a subsidiary of the China National Biotec Group (CNBG). The China National Pharmaceutical Group corporation (Sinopharm) is CNBG's parent company. The trade name of the vaccine is Covilo. The vaccine is also known as BBIBP-CorV. In the subsequent text the vaccine will be referred to as the COVID-19 vaccine BIBP